ETONHIGH SIGNALFINANCIAL10-K

ETON delivered exceptional financial performance with revenue doubling to $80M and operating losses narrowing significantly, while adding comprehensive cybersecurity risk management disclosures.

The company achieved remarkable 105% revenue growth alongside 986% operating cash flow improvement, suggesting strong commercial execution and cash conversion. The substantial reduction in operating losses (from -$2.6M to -$844K) indicates improving operational leverage and a clear path toward profitability.

Comparing 2026-03-19 vs 2025-03-18View on EDGAR →
FINANCIAL ANALYSIS

ETON demonstrated exceptional growth across all key metrics, with revenue doubling to $80M driving proportional increases in accounts receivable and gross profit to $42.7M. Operating cash flow surged nearly 1,000% to $10.5M while R&D spending increased 139% to $7.8M, reflecting reinvestment in the pipeline. The company's cash position strengthened to $25.9M despite higher current liabilities, indicating robust cash generation and improved financial health with operating losses narrowing dramatically by 67.5%.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+1180.8%
$26K$333K

Capital expenditure jumped 1180.8% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+986.1%
$969K$10.5M

Operating cash flow surged 986.1% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
+138.6%
$3.3M$7.8M

R&D investment increased 138.6% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+119.3%
$5.4M$11.8M

Receivables surged 119.3% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+104.9%
$39.0M$80.0M

Strong top-line growth of 104.9% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+93%
$19.9M$38.5M

Current liabilities surged 93% — significant near-term obligations; verify ability to meet short-term debt.

Gross Profit
P&L
+82.6%
$23.4M$42.7M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
+73.7%
$14.9M$25.9M

Cash position surged 73.7% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
+67.5%
-$2.6M-$844K

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
+47.7%
$41.0M$60.6M

Current assets grew 47.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-18
ADDED
false --12-31 FY 2025 Managing cybersecurity risk is critical to supporting our vision, enabling our strategy, and safely operating our business.
We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats.
Our process for identifying and assessing material risks from cybersecurity threats operates alongside our broader overall risk assessment process which covers all Company risks.
As part of this process, appropriate personnel collaborate with third-party subject matter experts to gather insights for identifying and assessing material risks associated with cybersecurity threats, their severity, and potential mitigations.
Further, we provide periodic training for all personnel regarding cybersecurity threats, with such training appropriate to the roles, responsibilities and access of the relevant Company personnel.
+7 more — sign up free →
REMOVED
Determining the fair value of inventory included making estimates of costs to complete and to sell semi-finished and finished goods inventory.
As of March 10, 2025, the registrant had 26,817,535 shares of common stock, $0.001 par value per share, outstanding.
We currently have seven commercial rare disease products: INCRELEX , ALKINDI SPRINKLE , GALZIN , PKU GOLIKE , Carglumic Acid, Betaine Anhydrous, and Nitisinone.
We have six additional product candidates in late-stage development: ET-400, ET-600, Amglidia , ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
ET-400 - We submitted to the FDA a New Drug Application ( NDA ) for the product in 2024, which was originally scheduled with a Prescription Drug User Fee Amendments ( PDUFA ) goal date of February 28, 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →